Company

Alpine Immune Sciences, Inc.

Headquarters: Seattle, WA, United States

Employees: 85

CEO: Dr. Mitchell H. Gold M.D.

NASDAQ: ALPN

Market Cap

$1.03 Billion

USD as of Jan. 1, 2024

Market Cap History

Alpine Immune Sciences, Inc. market capitalization over time

Evolution of Alpine Immune Sciences, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Alpine Immune Sciences, Inc.

Detailed Description

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Top 1-year algo backtest: +313.24%

$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Alpine Immune Sciences, Inc. has the following listings and related stock indices.


Stock: NASDAQ: ALPN wb_incandescent

Stock: FSX: 34LA wb_incandescent

Details

Headquarters:

201 Elliott Avenue West

Suite 230

Seattle, WA 98119

United States

Phone: 206 788 4545